Indian Wells, CA (PRWEB) June 17, 2015
Dr. John B. Jarding and Dr. George D. O’Clock were the co-founders of BionErgy Corpora-tion, which became Acuity Medical International. Jarding and O’Clock developed a treatment protocol and electrotherapeutic device using a frequency variable pulsed waveform approach (TESMAC and TheraMac). O’Clock invented the device design concept and orchestrated the technical approach while Jarding developed the initial therapeutic protocol. The TESMAC and TheraMac devices evolved from the Jarding – O’Clock patents which are now owned by The Eye Machine. This device and protocol completed an FDA approved double-blind clinical trial, resulting in a successful FDA review of Phase I. This review was held in Rockville, MD, on January 18, 2005.
Acuity’s Phase I approval, now included in the Eye Machine’s intellectual property portfolio, may shorten the time frame for FDA approval of TEM’s non-invasive treatment of age-related macular degeneration. The Eye Machine submitted the winning bid against four other interested parties vying for Acuity’s intellectual property and other assets.
Dr. George O’Clock, Chief Science Advisor for The Eye Machine, created TEM’s new thera-peutic device which can help mitigate the effects of age-related macular degeneration and diabetic retinopathy.
About The Eye Machine:
The Eye Machine, LLC was formed to develop, manufacture, and lease to medical profes-sionals an electrotherapeutic device to treat visual disease, providing a pulsed micro-current output delivered to the retina by way of a closed eyelid. This treatment method can help mitigate the effects of age-related macular degeneration and diabetic retinopathy.
The Eye Machine’s pulsed micro-current therapy represents a new, non-invasive treatment for all forms of macular degeneration. The device output signal is structured to provide a range and pattern of frequencies to stimulate the desired physiologic response at the retinal level. This low current has been shown by studies to stimulate the production of the active transport enzyme, adenosine triphosphate (“ATP”), which facilitates the movement of nutri-tion from the blood to the cell. According to recent studies, this treatment improves per-meability of the blood vessel membranes and cells, allows better oxygen and nutrition deliv-ery to the cells, metabolism, and removal of by-products from the cells. Through these mechanisms, pulsed micro-current therapy improves retinal pigment epithelium (“RPE”) effi-ciency and in so doing may restore and/or improve retinal function.
For more information contact:
Vice President of Marketing